Services for the Development of Products Focused on Women's Health

Men and women experience many of the same health problems. Although the symptoms may be similar, some may affect women more severely and the care necessary to treat them can differ significantly. Women also experience unique health issues and conditions - from pregnancy and menopause to gynecological conditions, such as vaginal infections which can ultimately affect their well-being and quality of life. As a natural extension of our infectious disease, cancer and prevention programs, ImQuest BioSciences offers services that are specific to the needs of women's health, utilizing PrevSENS, MicroSENS, OncoSENS, ToxiSENS, and PharmaSENS.

Topical Microbicides for the Prevention of HIV
The development of topical microbicides for use in the prevention of the sexual transmission of HIV has become a high priority for the National Institutes of Health (NIH) and World Health Organization (WHO). PrevSENS, ImQuest BioSciences' microbicide development program, utilizes a wide range of microbiological, biochemical and molecular technologies to assess the activity and toxicity of agents against HIV including:

  • Antiviral activity and cellular toxicity
  • Range of action
  • Mechanism of action
  • Combination microbicide activity
  • Selection and characterization of resistant organisms

Sexually Transmitted and Other Vaginal Infections
Sexually transmitted infections (STIs) can often have a more serious effect in women than men. Untreated STIs cause infertility in at least 24,000 women each year in the United States. STIs often go untreated in women because symptoms are less obvious than in men or are more likely to be confused with other less serious conditions, such as yeast infections or bacterial vaginosis. ImQuest BioSciences has the capability to evaluate potential inhibitors against organisms that cause infections in the vagina and urinary tract as part of our MicroSENS and ViroSENS programs including:

  • HIV
  • HSV-1
  • HSV-2
  • HPV
  • Hepatitis viruses
  • Neisseria gonorrhoeae
  • Chlamydia trachomatis
  • Trichomonas vaginalis
  • Candida albicans
  • Gardnerella vaginalis

Cancer is a deadly disease with high morbidity and mortality in the human population. Certain types of cancers affect primarily (or exclusively) women. At ImQuest BioSciences, we utilize the OncoSENS, ToxiSENS and PharmaSENS programs, to assess efficacy, safety and pharmaceutical properties (including formulation analysis) of novel small molecules and biologics for the treatment of women's cancers including:

  • Breast cancer
  • Endometrial cancer
  • Cervical cancer
  • Ovarian cancer

Osteoporosis, a disease more common in women, causes bones to become fragile and more susceptible to breaking. Fractures and the subsequent pain and disability can seriously affect women's health and their quality of life. Some women - most commonly those who don't have access to health care - experience fractures that could have been prevented if their osteoporosis had been treated. ImQuest BioSciences uses the ToxiSENS program to assess:

  • In vitro toxicity to osteoclasts
  • In vitro toxicity to osteoblasts
ImQuest BioSciences is a preclinical contract research and development organization (CRO) that provides service to evaluate the potential efficacy of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory disease, including in vitro toxicology and pharmaceutical product characterization services.